Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease - Romero-Bueno, F.; Diaz del Campo, P.; Trallero-Araguás, E.; Ruiz-Rodríguez, J.C.; Castellvi, I.; Rodriguez-Nieto, M.J.; Martínez-Becerra, M.J.; Sanchez-Pernaute, O.; Pinal-Fernandez, I.; Solanich, X.; Gono, T.; Gonzalez-Gay, M.A.; et al. (Seminars in arthritis and rheumatism, 2020)
Keywords: Basiliximab; Consensus; Cyclophosphamide; Cyclophosphamide - therapeutic use; Cyclosporine; Dermatomyositis; Dermatomyositis - complications; Dermatomyositis - drug therapy; Dermatomyositis - genetics; Drug Therapy, Combination; Extracorporeal membrane oxygenation; Glucocorticoid; Glucocorticoids - therapeutic use; Humans; Immunosuppressive Agents - therapeutic use; Intensive care; Interferon-Induced Helicase, IFIH1 - genetics; Intravenous immunoglobulins; Lung Diseases, Interstitial - complications; Lung Diseases, Interstitial - drug therapy; Lung transplant; Mycophenolate; Plasmapheresis; Polymixyn B hemoperfusion; Rapidly progressive interstitial lung disease; Review; Rituximab; Syndrome; systematic; Tacrolimus; Tofacitinib; Polymixyn B hemoperfusion; Intensive care; Extracorporeal membrane oxygenation; Intravenous immunoglobulins; Dermatomyositis; Rituximab; Cyclosporine; Review; systematic; Glucocorticoid; Plasmapheresis; Mycophenolate; Cyclophosphamide; Tacrolimus; Tofacitinib; Rapidly progressive interstitial lung disease; Basiliximab; Lung transplant